Trial Profile
A Phase 2, Randomized, Double-blind, Placebo-controlled, Multiple Dose, Parallel Group Study to Evaluate the Efficacy, Safety, and Pharmacodynamics of RM-131 Administered to Patients With Chronic Constipation
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 30 Sep 2016
Price :
$35
*
At a glance
- Drugs Relamorelin (Primary)
- Indications Constipation
- Focus Adverse reactions; Therapeutic Use
- Sponsors Rhythm; Rhythm Pharmaceuticals
- 14 Oct 2015 Results (n = 18) published in the Digestive Diseases and Sciences
- 24 Oct 2014 Primary endpoint has been met (effect of relamorelin on colonic transit), according to a Rhythm Pharmaceuticals media release.
- 24 Oct 2014 Results published in the Media Release.